"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000970
|
| MeSH Number(s) |
D27.505.954.248
|
| Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
- Chemotherapeutic Anticancer Drug
- Drug, Chemotherapeutic Anticancer
- Antitumor Drugs
- Drugs, Antitumor
- Cancer Chemotherapy Agents
- Agents, Cancer Chemotherapy
- Chemotherapy Agents, Cancer
- Cancer Chemotherapy Drugs
- Chemotherapy Drugs, Cancer
- Drugs, Cancer Chemotherapy
- Chemotherapeutic Anticancer Agents
- Agents, Chemotherapeutic Anticancer
- Anticancer Agents
- Agents, Anticancer
- Antitumor Agents
- Agents, Antitumor
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 5 | 2 | 7 |
| 1996 | 13 | 2 | 15 |
| 1997 | 8 | 1 | 9 |
| 1998 | 22 | 5 | 27 |
| 1999 | 9 | 9 | 18 |
| 2000 | 16 | 6 | 22 |
| 2001 | 23 | 6 | 29 |
| 2002 | 36 | 11 | 47 |
| 2003 | 30 | 11 | 41 |
| 2004 | 37 | 13 | 50 |
| 2005 | 31 | 19 | 50 |
| 2006 | 35 | 21 | 56 |
| 2007 | 44 | 16 | 60 |
| 2008 | 33 | 18 | 51 |
| 2009 | 40 | 24 | 64 |
| 2010 | 52 | 28 | 80 |
| 2011 | 63 | 18 | 81 |
| 2012 | 56 | 27 | 83 |
| 2013 | 54 | 23 | 77 |
| 2014 | 71 | 22 | 93 |
| 2015 | 82 | 32 | 114 |
| 2016 | 61 | 29 | 90 |
| 2017 | 57 | 26 | 83 |
| 2018 | 44 | 24 | 68 |
| 2019 | 41 | 25 | 66 |
| 2020 | 34 | 19 | 53 |
| 2021 | 46 | 16 | 62 |
| 2022 | 20 | 2 | 22 |
| 2023 | 38 | 0 | 38 |
| 2024 | 15 | 21 | 36 |
| 2025 | 8 | 1 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
Designing live bacterial therapeutics for cancer. Adv Drug Deliv Rev. 2025 Jun; 221:115579.
-
Pharmacogenomics of chemotherapy induced peripheral neuropathy using an electronic health record-derived definition: a genome-wide association study. Support Care Cancer. 2025 Apr 08; 33(5):362.
-
NEPA (Netupitant/Palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy Who Experienced Breakthrough CINV in Cycle 1 of Chemotherapy: A Phase II Clinical Trial. Cancer Med. 2025 Apr; 14(7):e70549.
-
Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates. Future Oncol. 2025 Apr; 21(10):1261-1272.
-
Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy. Biochem Pharmacol. 2025 Jun; 236:116850.
-
Distinguishing Daratumumab from Endogenous Monoclonal Proteins in Serum from Multiple Myeloma Patients Using an Automated Mass Spectrometry System. J Appl Lab Med. 2025 Mar 03; 10(2):235-249.
-
Rational Design and Optimization of a Potent IDO1 Proteolysis Targeting Chimera (PROTAC). J Med Chem. 2025 Feb 27; 68(4):4961-4987.
-
Adapted Exosomes for Addressing Chemotherapy-induced Premature Ovarian Insufficiency. Stem Cell Rev Rep. 2025 Apr; 21(3):779-796.
-
Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study. Lung Cancer. 2025 Apr; 202:108417.
-
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2025 Feb 27; 392(9):875-891.